<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-C
REPORT BY ISSUER OF SECURITIES QUOTED ON NASDAQ
INTERDEALER QUOTATION SYSTEM
FILED PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
AND RULE 13a-17 OR 15d-17 THEREUNDER
GENETICS INSTITUTE, INC.
- --------------------------------------------------------------------------------
(Exact name of issuer as specified in charter)
87 CambridgePark Dr., Cambridge, MA 02140
- --------------------------------------------------------------------------------
(Address of principal executive offices)
Issuer's telephone number, including area code (617)876-1170
---------------------------------
I. CHANGE IN NUMBER OF SHARES OUTSTANDING
Indicate any change (increase or decrease) of 5% or more in the number of shares
outstanding:
1. Title of security: Depositary Shares, each representing one share of
Common Stock, $0.01 par value per share, subject to
a call option held by AHP Biotech Holdings, Inc. and
evidenced by a depositary receipt
------------------------------------------------------
2. Number of shares outstanding before the change: 11,433,204
--------------------------
3. Number of shares outstanding after the change: 12,694,729
---------------------------
4. Effective date of change: May 31, 1996
------------------------------------------------
5. Method of change: Specify method (such as merger, acquisition, exchange,
distribution, stock split, reverse split, acquisition of stock for
treasury, etc.) Warrant and stock option exercises, issuances
--------------------------------------------------------
under Employee Stock Purchase Plan.
-------------------------------------------------------------------------
Give brief description of transaction: Issuance of stock as a result
---------------------------------
of (1) exercises of stock options under stock option plan, (2) exercise
-------------------------------------------------------------------------
of warrants and (3) issuances under Employee Stock Purchase Plan.
-------------------------------------------------------------------------
II. CHANGE IN NAME OF ISSUER
1. Name prior to change: N/A
---------------------------------------------------
2. Name after change: N/A
-----------------------------------------------------
3. Effective date of charter amendment changing name: N/A
----------------------
4. Date of shareholder approval of change, if required:
--------------------
Date: June 6, 1996
/s/ Garen G. Bohlin
-----------------------------------------------------------------
Garen G. Bohlin, Executive Vice President & Chief Financial Officer
